The RASSF10 has been identified as a tumor suppressor in human colorectal cancer (CRC). However, the expression of RASSF10 in patients with CRC has not been evaluated for its potential use as a biomarker in the diagnosis and prognosis assessment of CRC. We analyzed the expression of RASSF10 mRNA (n=30) and protein (n=205) in CRC and matched noncancerous colon tissue samples to explore the relationships among RASSF10 expression, clinicopathological factors, and prognosis in patients with CRC. Our results showed that the expression of RASSF10 mRNA and protein in CRC-adjacent tissues was higher than that in CRC tissues. Low RASSF10 expression was associated with the T stage (P=.037, odds ratio, 0.664; 95% confidence interval, 0.452-0.975) and the N stage (P<.001, odds ratio, 0.318; 95% confidence interval, 0.184-0.549) of the tumors. In addition, univariate analysis revealed that patients with CRC with lower RASSF10 expression had poorer overall survival (OS; P<.001) and disease-free survival (DFS; P<.001). The 5-year OS and DFS rates were 48.2% and 28.3%, respectively, in patients with low RASSF10 expression and 82.2% and 62.6%, respectively, in patients with high RASSF10 expression. Multivariate Cox regression analysis revealed that the strongest predictors of OS and DFS were RASSF10 expression (P<.001 and P<.001, respectively), T stage (P=.003 and P=.009, respectively), and N stage (P=.005 and P=.026, respectively). These results demonstrate that low expression of RASSF10 in CRC tissues is significantly correlated with poor survival after curative resection and may serve as a useful biomarker predictive of CRC prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.humpath.2016.12.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.
Front Oncol
October 2024
Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- The study investigates the genetic landscape of non-small cell lung cancer (NSCLC) and its impact on resistance to osimertinib, using liquid biopsy to identify resistance mechanisms.
- It analyzed plasma-circulating free DNA (cfDNA) and circulating tumor cells (CTCs) from 30 NSCLC patients, detecting various molecular alterations that could indicate resistance to treatment.
- Findings revealed discrepancies in the mutation presence between cfDNA and CTCs, suggesting that combining both analyses provides a broader understanding of resistance and potential treatment options.
A prognostic model established using bile acid genes to predict the immunity and survival of patients with gastrointestinal cancer.
Environ Toxicol
October 2024
Department of General Surgical Medicine, The First Medicine Center of PLA General Hospital, Beijing, China.
Background: The metabolism of abnormal bile acids (BAs) is implicated in the initiation and development of gastrointestinal (GI) cancer. However, there was a lack of research on the molecular mechanisms of BAs metabolism in GI.
Methods: Genes involved in BAs metabolism were excavated from public databases of The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) database, and Molecular Signatures Database (MSigDB).
Mechanistic analysis of Th2-type inflammatory factors in asthma.
J Thorac Dis
December 2023
Department of Respiratory Diseases, The First Affiliated Hospital of Hainan Medical University, Hainan Province Clinical Medical Center of Respiratory Diseases, Haikou, China.
Background: The main pathological features of asthma are widespread chronic inflammation of the airways and restricted ventilation due to airway remodeling, which involves changes in a range of regulatory pathways. While the role of T helper type 2 (Th2)-related inflammatory factors in this process is known, the detailed understanding of how genes affect protein functions during airway remodeling is still lacking. This study aims to fill this knowledge gap by integrating gene expression data and protein function analysis, providing new scientific insights for a deeper understanding of the mechanisms of airway remodeling and for further development of asthma treatment strategies.
View Article and Find Full Text PDFRASSF10 exhibits tumor‑suppressing potential involving tumor proliferation, metastasis and epithelial‑mesenchymal transition in esophageal squamous cell carcinoma.
Oncol Rep
April 2022
Department of Cardio‑Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China.
Growing evidence indicates that Ras‑association domain family 10 () is a novel tumor‑suppressor gene that is involved in the inhibition of tumor progression and metastasis; however, the biological functions and molecular mechanisms of RASSF10 in esophageal squamous cell carcinoma (ESCC) have not yet been thoroughly elucidated. The expression of RASSF10 in ESCC tissues and adjacent non‑tumor tissues was investigated employing quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC) assays of tissue microarrays. The function of RASSF10 in ESCC cell growth, migration and invasion was determined by CCK‑8, colony formation, scratch wound healing and Transwell invasion assays, respectively.
View Article and Find Full Text PDFMolecular basis for RASSF10/NPM/RNF2 feedback cascade-mediated regulation of gastric cancer cell proliferation.
J Biol Chem
August 2021
Laboratory of Molecular Cell Biology, National Cancer Tissue Biobank, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology-Madras, Chennai, India. Electronic address:
Ras-association domain family (RASSF) proteins are encoded by numerous tumor suppressor genes that frequently become silenced in human cancers. RASSF10 is downregulated by promoter hypermethylation in cancers and has been shown to inhibit cell proliferation; however, the molecular mechanism(s) remains poorly understood. Here, we demonstrate for the first time that RASSF10 inhibits Cdk1/cyclin-B kinase complex formation to maintain stable levels of cyclin-B for inducing mitotic arrest during cell cycle.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!